| ID Source | ID |
|---|---|
| PubMed CID | 444764 |
| CHEMBL ID | 139050 |
| CHEBI ID | 44493 |
| SCHEMBL ID | 4315667 |
| Synonym |
|---|
| OBA , |
| 2-(oxalyl-amino)-benzoic acid |
| CHEBI:44493 , |
| 2-[(carboxycarbonyl)amino]benzoic acid |
| 2-(oxaloamino)benzoic acid |
| DB02622 |
| 1C85 |
| CHEMBL139050 , |
| 2-(carboxyformamido)benzoic acid |
| bdbm50118789 |
| SCHEMBL4315667 |
| benzoic acid,2[(carboxycarbonyl)amino]- |
| 5651-01-4 |
| 2-oxaloaminobenzoic acid |
| Q27093587 |
| PD007813 |
| benzoic acid, 2-[(carboxycarbonyl)amino]- |
| DTXSID101034398 |
| 2-carboxyoxanilic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds." | ( Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. Andersen, HS; Bakir, F; Branner, S; Christensen, MS; Collins, T; Hansen, TK; Iversen, LF; Jeppesen, L; Judge, L; Lau, JF; Moran, EJ; Mortensen, SB; Møller, NP; Newman, MJ; Olsen, OH; Ripka, WC; Shahbaz, M; Su, J; Sørensen, AL; Vo, T, 2002) | 0.31 |
| Class | Description |
|---|---|
| (oxaloamino)benzoic acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, PROTEIN (PROTEIN-TYROSINE PHOSPHATASE 1B) | Homo sapiens (human) | Ki | 23.0000 | 14.0000 | 18.5000 | 23.0000 | AID977610 |
| Chain A, PROTEIN (PROTEIN-TYROSINE PHOSPHATASE 1B) | Homo sapiens (human) | Ki | 23.0000 | 14.0000 | 18.5000 | 23.0000 | AID977610 |
| Chain A, PROTEIN (PROTEIN-TYROSINE PHOSPHATASE 1B) | Homo sapiens (human) | Ki | 23.0000 | 14.0000 | 18.5000 | 23.0000 | AID977610 |
| Chain A, PROTEIN-TYROSINE PHOSPHATASE 1B | Homo sapiens (human) | Ki | 23.0000 | 14.0000 | 18.5000 | 23.0000 | AID977610 |
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | Ki | 23.0000 | 4.3000 | 4.3000 | 4.3000 | AID439576 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | Ki | 14,483,666,276.6362 | 0.1900 | 4.8327 | 9.6000 | AID165018; AID257651; AID483153 |
| Type-1 angiotensin II receptor | Homo sapiens (human) | Ki | 870.0000 | 0.0002 | 0.1837 | 4.7000 | AID165337 |
| Type-2 angiotensin II receptor | Homo sapiens (human) | Ki | 870.0000 | 0.0002 | 0.5650 | 7.7790 | AID165337 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||